Contact Us 联系我们
Contact Us 联系我们
Contact Us 联系我们

Investors

Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements



DateTitle
18/07/2018FDA Grants Bisantrene Rare Paediatric Disease DesignationDownload
16/07/2018Trading HaltDownload
13/07/2018Appendix 3B-Issue of OptionsDownload
13/07/2018Appendix 3BDownload
02/07/2018Cleansing NoticeDownload
02/07/2018Appendix 3BDownload
02/07/2018Expiry of Unlisted OptionsDownload
02/07/2018Performance Share Milestones MetDownload
26/06/2018Bisantrene poster presented at French Leukaemia ConferenceDownload
22/06/2018Release of Securities from EscrowDownload
1  2  3  4  5  6  7  8  

ASX: RAC

Price

Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2018 Race Oncology. Website By Glide Agency